2. Search Result
Search Result
Results for "

heterodimers

" in MedChemExpress (MCE) Product Catalog:

54

Inhibitors & Agonists

2

Fluorescent Dye

7

Peptides

5

Inhibitory Antibodies

4

Natural
Products

5

Isotope-Labeled Compounds

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-125978
    JY-3-094

    		c-Myc Cancer
    JY-3-094 is a Myc inhibitor that inhibits Myc-Max heterodimer formation (IC50: 33 μM) .
    JY-3-094
  • HY-P99676
    Izalontamab

    SI-B001

    		 EGFR Cancer
    Izalontamab (SI-B001) is a bispecific anti-EGFR/HER3 monoclonal antibody with high selectivity for EGFR/HER3 heterodimer. Izalontamab can be used for the research of cancer .
    Izalontamab
  • HY-Y1666
    2,2′-Dipyridyl disulfide

    		Biochemical Assay Reagents Others
    2,2′-Dipyridyl disulfide is a useful reagent for the determination of sulfhydryl groups. 2,2′-Dipyridyl disulfide is a common reagent in peptide chemistry, often used in oxidation–reduction condensations to form peptide bonds or in coupling reactions to form disulfide-linked heterodimers .
    2,2′-Dipyridyl disulfide
  • HY-P3229
    SN52
    2 Publications Verification

    		 NF-κB Cancer
    SN52 is a potent, competitive, and cell-permeable inhibitor of NF-κB2. SN52 is a variant of the SN50 peptide and inhibits the nuclear translocation of p52-RelB heterodimers. SN52 has a strong radiosensitization effect on prostate cancer cells. SN52 can be used for cancer research .
    SN52
  • HY-P990244
    Anti-Rat FcRn heavy chain heterodimers Antibody (2G3)

    		Fc Receptor (FcR) Others
    Anti-Rat FcRn heavy chain heterodimers Antibody (2G3) is a mouse-derived IgG1 type antibody inhibitor, targeting to rat FcRn heavy chain heterodimers.
    Anti-Rat FcRn heavy chain heterodimers Antibody (2G3)
  • HY-163829
    TLR2 agonist 1

    		Toll-like Receptor (TLR) NF-κB Cancer
    TLR2 agonist 1 (Compound R-7d) is an agonist for human toll-like receptor 2 (TLR 2) with an EC50 of 116 pM. TLR2 agonist 1 enhances NF-κB promoter activation through TLR2/TLR1 heterodimers .
    TLR2 agonist 1
  • HY-149536
    TWIK-1/TREK-1-IN-1

    		Potassium Channel Neurological Disease
    TWIK-1/TREK-1-IN-1 (compound 2a) is an inhibitor of the TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 9.36 μM and 14.6 μM, respectively, and has antidepressant-like effects .
    TWIK-1/TREK-1-IN-1
  • HY-P10405
    TAT-D1 peptide

    		Dopamine Receptor Neurological Disease
    TAT-D1 peptide is a selective D1-D2 heterogeneous antagonist. TAT-D1 peptide destroys the heterodimer of the D1-D2 receptor by interacting with the specific domain of the D2 receptor through its unique amino acid sequence, in particular the two glutamate residues at the C terminal of the D1 receptor. TAT-D1 peptide can be used to study the role of D1-D2 receptor heterodimers in the regulation of depressive and anxiety-like behaviors .
    TAT-D1 peptide
  • HY-142944
    DNA-PK-IN-2

    		DNA-PK Cancer
    DNA-PK-IN-2 is a potent inhibitor of DNA-PK. DNA-dependent protein kinase (DNA-PK) is a DNA-PK enzyme complex composed of Ku70/Ku80 heterodimer and DNA-dependent protein kinase catalytic subunit (DNA-PKcs). DNA-PK-IN-2 has the potential for the research of cancer diseases (extracted from patent WO2021136462A1, compound 1) .
    DNA-PK-IN-2
  • HY-142943
    DNA-PK-IN-1

    		DNA-PK Cancer
    DNA-PK-IN-1 is a potent inhibitor of DNA-PK. DNA-dependent protein kinase (DNA-PK) is a DNA-PK enzyme complex composed of Ku70/Ku80 heterodimer and DNA-dependent protein kinase catalytic subunit (DNA-PKcs). DNA-PK-IN-1 has the potential for the research of cancer diseases (extracted from patent WO2021136463A1, compound 1) .
    DNA-PK-IN-1
  • HY-P99184
    Abrilumab

    		Integrin Infection Inflammation/Immunology Cancer
    Abrilumab is a fully human monoclonal antibody directed against α4β7. Abrilumab selectively binds the α4β7 integrin heterodimer. Abrilumab can be used for the research of inflammatory bowel disease (IBD) .
    Abrilumab
  • HY-110333
    BMS-599626 dihydrochloride

    		EGFR Cancer
    BMS-599626 dihydrochloride is a small molecule pan-HER (human epidermal growth factor receptor) kinase inhibitor. BMS-599626 dihydrochloride primarily targets HER1 (IC50=20 nmol/L) and HER2 (IC50=30 nmol/L) kinase activity in the HER family. BMS-599626 inhibits the kinase activity of HER1 and HER2 by competing with their ATP-binding sites, and can inhibit the downstream signaling pathway by blocking the heterodimer formation of HER1 and HER2. BMS-599626 dihydrochloride can be used to study the antitumor effects of multiple HER1 or HER2 overexpressed tumor models .
    BMS-599626 dihydrochloride
  • HY-122683
    sAJM589
    1 Publications Verification

    		 c-Myc Cancer
    sAJM589 is a Myc inhibitor which potently disrupts the Myc-Max heterodimer with an IC50 of 1.8 μM .
    sAJM589
  • HY-P10703
    SAF-p2

    		Biochemical Assay Reagents Others
    SAF-p2 is a self-assembling fiber peptide that can form sticky-ended heterodimers by assembling with SAF-p2 (HY-P10702) through complementary amino acid sequences. These heterodimers further self-assemble into long-chain fiber structures. SAF-p2 is promising for the development of nanomaterials in the biomedical field .
    SAF-p2
  • HY-P10702
    SAF-p1

    		Biochemical Assay Reagents Others
    SAF-p1 is a self-assembling fiber peptide that can form sticky-ended heterodimers by assembling with SAF-p2 (HY-P10703) through complementary amino acid sequences. These heterodimers further self-assemble into long-chain fiber structures. SAF-p1 is promising for the development of nanomaterials in the biomedical field .
    SAF-p1
  • HY-P1275
    Tertiapin-Q
    2 Publications Verification

    		 Potassium Channel Cardiovascular Disease
    Tertiapin-Q is a highly selective blocker of GIRK1/4 heterodimer and ROMK1 (Kir1.1).
    Tertiapin-Q
  • HY-115672
    KS15
    2 Publications Verification

    		 Cryptochrome Cancer
    KS15 is an inhibitor of the interactions between cryptochromes (CRYs: CRY1 and CRY2) and the CLOCK:BMAL1 heterodimer. KS15 impairs the feedback actions of CRYs on E-box-dependent transcription (EC50=4.9 μM) by CLOCK:BMAL1 heterodimer, an indispensable transcriptional regulator of the mammalian circadian clock. Anti-proliferative activity .
    KS15
  • HY-17029
    Epothilone B
    5 Publications Verification

    EPO 906; Patupilone

    		 Microtubule/Tubulin Fungal Apoptosis Antibiotic Bacterial Infection Cancer
    Epothilone B is a microtubule stabilizer with a Ki of 0.71μM. It acts by binding to the αβ-tubulin heterodimer subunit which causes decreasing of αβ-tubulin dissociation.
    Epothilone B
  • HY-112374
    NPAS3-IN-1

    		HIF/HIF Prolyl-Hydroxylase Neurological Disease
    NPAS3-IN-1 is a potent inhibitor of NPAS3-ARNT heterodimerization and regulates NPAS3 transcription by disrupting the heterodimerization of NPAS3 with ARNT at the cellular level .
    NPAS3-IN-1
  • HY-167290
    N-(Azido-PEG3)-N-bis(PEG3-NHS ester)

    		Biochemical Assay Reagents Others
    N-(Azido-PEG3)-N-bis(PEG3-NHS ester) is a trifunctional linker that can be used for synthesis of a bispecific heterodimer .
    N-(Azido-PEG3)-N-bis(PEG3-NHS ester)
  • HY-120875
    HX600

    		RAR/RXR Neurological Disease
    HX600 is a synthetic agonist for RXR (Retinoid X Receptor) heterodimer complex. HX600 prevents ischemia-induced neuronal damage. HX600 has orally bioactivity .
    HX600
  • HY-168633
    PSMA/GRPR ligand 1

    		Bombesin Receptor PSMA Cancer
    PSMA/GRPR ligand 1 (compound 3 ) is a bispecific PSMA/GRPR ligand that shows dual targeting for PSMA(+) and GRPR(+) tumors .
    PSMA/GRPR ligand 1
  • HY-121896
    DSHN

    		SHP2 Cancer
    DSHN is a potent small heterodimer partner (SHP) activator. DSHN inhibits Ccl2 expression and secretion by inhibiting p65 activation of Ccl2 promoter activity. DSHN can be used in research of cancer .
    DSHN
  • HY-104006
    CYM51010

    		Opioid Receptor Neurological Disease
    CYM51010 is a biased ligand of μ-opioid receptor – δ-opioid receptor heterodimers with an EC50 of 403 nM. CYM51010 exhibits anti-nociceptive activity similar to morphine but with a decreased levels of tolerance development and withdrawal symptoms .
    CYM51010
  • HY-108523
    LG100754

    UVI 2112

    		 RAR/RXR Metabolic Disease
    LG100754 (UVI 2112) is a RXR dimers modulater. LG100754 acts as a RXR:RXR homodimer antagonist, but functions as a agonist towards RXR:PPARα and RXR:PPARγ heterodimers. LG100754 is an insulin sensitizer that functions through RXR .
    LG100754
  • HY-17029R
    Epothilone B (Standard)

    EPO 906 (Standard); Patupilone (Standard)

    		 Reference Standards Microtubule/Tubulin Fungal Apoptosis Antibiotic Bacterial Infection Cancer
    Epothilone B (Standard) is the analytical standard of Epothilone B. This product is intended for research and analytical applications. Epothilone B is a microtubule stabilizer with a Ki of 0.71μM. It acts by binding to the αβ-tubulin heterodimer subunit which causes decreasing of αβ-tubulin dissociation.
    Epothilone B (Standard)
  • HY-W754654
    Epothilone B-d3 (synthetic)

    		Isotope-Labeled Compounds Microtubule/Tubulin Fungal Apoptosis Bacterial Antibiotic Cancer
    Epothilone B-d3 (synthetic) is the deuterium labeled Epothilone B (HY-17029). Epothilone B is a microtubule stabilizer with a Ki of 0.71μM. It acts by binding to the αβ-tubulin heterodimer subunit which causes decreasing of αβ-tubulin dissociation.
    Epothilone B-d3 (synthetic)
  • HY-19528
    SAH
    Maximum Cited Publications
    14 Publications Verification

    SAH (S-Adenosylhomocysteine)

    		 Endogenous Metabolite Metabolic Disease
    SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 µM .
    SAH
  • HY-149538
    TWIK-1/TREK-1-IN-3

    		Potassium Channel Neurological Disease
    TWIK-1/TREK-1-IN-3 (compound 2h) is an inhibitor of TWIK-related potassium channel (Potassium Channel) TREK-1. TREK-1 contains a two-pore domain potassium (K2p) channel that dimerizes into TREK-1 homodimer and TWIK-1/TREK-1 heterodimer, and is an important antidepressant target. TWIK-1/TREK-1-IN-3 targets TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 9.74 μM and 16.5 μM, respectively, and has antidepressant-like effects .
    TWIK-1/TREK-1-IN-3
  • HY-P1949
    Cyclic MKEY

    		CXCR Cardiovascular Disease Cancer
    Cyclic MKEY is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY also protects against stroke-induced brain injury in mice .
    Cyclic MKEY
  • HY-B0551S
    Doxapram-d8

    		Potassium Channel Isotope-Labeled Compounds Neurological Disease
    Doxapram-d8 is deuterated labeled Doxapram (HY-B0551). Doxapram inhibits TASK-1, TASK-3 and TASK-1/TASK-3 heterodimer channels with EC50s of 410 nM, 37 μM and 9 μM, respectively.
    Doxapram-d8
  • HY-P1949A
    Cyclic MKEY TFA

    		CXCR Cardiovascular Disease Cancer
    Cyclic MKEY TFA is a synthetic cyclic peptide inhibitor of CXCL4-CCL5 heterodimer formation, which protects against atherosclerosis and aortic aneurysm formation by mediating inflammation. Cyclic MKEY TFA also protects against stroke-induced brain injury in mice .
    Cyclic MKEY TFA
  • HY-122727
    STL127705
    5+ Cited Publications

    		 DNA-PK Apoptosis Cancer
    STL127705 (Compound L) is a potent Ku 70/80 heterodimer protein inhibitor with an IC50 of 3.5 μM. STL127705 interferes the binding of Ku70/80 to DNA and by inhibits the activation of the DNA-PKCS kinase. STL127705 shows antiproliferative and anticancer activity. STL127705 induces apoptosis .
    STL127705
  • HY-19528S
    SAH-d4

    SAH (S-Adenosylhomocysteine)-d4

    		 Endogenous Metabolite Metabolic Disease
    SAH-d4 is the deuterium labeled SAH. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM .
    SAH-d4
  • HY-19528S2
    SAH-13C10

    		Endogenous Metabolite Metabolic Disease
    SAH- 13C10 is the 13C labeled SAH . SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM .
    SAH-13C10
  • HY-19528R
    SAH (Standard)

    SAH (S-Adenosylhomocysteine) (Standard)

    		 Reference Standards Endogenous Metabolite Metabolic Disease
    SAH (Standard) is the analytical standard of SAH. This product is intended for research and analytical applications. SAH (S-Adenosylhomocysteine) is an amino acid derivative and a modulartor in several metabolic pathways. It is an intermediate in the synthesis of cysteine and adenosine . SAH is an inhibitor for METTL3-METTL14 heterodimer complex (METTL3-14) with an IC50 of 0.9 μM .
    SAH (Standard)
  • HY-E70080
    Vaccinia virus capping enzyme

    		Biochemical Assay Reagents Others
    Vaccinia virus capping enzyme is a transcription initiation factor. Vaccinia virus capping enzyme is a heterodimer of D1 (844 aa) and D12 (287 aa) polypeptides that executes all three steps in m7GpppRNA synthesis. Vaccinia virus capping enzyme has been used widely as a reagent for capping and cap-labeling RNAs in vitro .
    Vaccinia virus capping enzyme
  • HY-155161
    COX-2/15-LOX-IN-4

    		Lipoxygenase COX Inflammation/Immunology
    COX-2/15-LOX-IN-4 (compound 5i) is a dual inhibitor of COX-2/15-LOX with IC50s of 0.075 μM and 1.97 μM, respectively. COX-2/15-LOX-IN-4 can inhibit LPS-induced cell production of promoting cytokines (IL-6, ROS) with specific anti-inflammatory activity .
    COX-2/15-LOX-IN-4
  • HY-155160
    COX-2/15-LOX-IN-3

    		Lipoxygenase COX Inflammation/Immunology
    COX-2/15-LOX-IN-3 (compound 5k) is a dual inhibitor of COX-2/15-LOX with IC50s of 0.075 μM and 1.97 μM, respectively. COX-2/15-LOX-IN-3 can inhibit LPS-induced cell production of promoting cytokines (IL-6, ROS, and NO), with specific anti-inflammatory activity .
    COX-2/15-LOX-IN-3
  • HY-138967
    BRF110

    		Nuclear Hormone Receptor 4A/NR4A RAR/RXR Neurological Disease
    BRF110 is the selective, orally active rexinoid for Nurr1-RXRα, that selectively activates the Nurr1-RXRα heterodimer with an EC50 of 0.9 μM in SH-SY5Y. BRF110 upregulates the expression of BDNF, exhibits neuroprotective activity against MPP+ induced toxicity. BRF110 can cross blood-brain barrier .
    BRF110
  • HY-150511
    3-(3-Phenoxybenzyl)amino-β-carboline

    		Microtubule/Tubulin Apoptosis Cancer
    3-(3-Phenoxybenzyl)amino-β-carboline is a potent tubulin inhibitor. 3-(3-Phenoxybenzyl)amino-β-carboline promotes selective degradation of αβ-tubulin heterodimers. 3-(3-Phenoxybenzyl)amino-β-carboline induces G2/M phase cell cycle arrest and apoptosis. 3-(3-Phenoxybenzyl)amino-β-carboline exhibits anticancer activity .
    3-(3-Phenoxybenzyl)amino-β-carboline
  • HY-117182
    LG190178

    		Apoptosis VD/VDR RAR/RXR Metabolic Disease Inflammation/Immunology Cancer
    LG190178 is a non-steroidal vitamin D receptor (VDR) ligand that can induce the formation of heterodimer complexes between VDR and retinoid X receptor (RXR), stabilizing the agonistic conformation of the VDR ligand-binding domain and promoting its interaction with co-activators. LG190178 has functions in regulating calcium homeostasis, bone mineralization, as well as cell proliferation, differentiation, and apoptosis, making it useful for research in psoriasis, osteoporosis, and cancer .
    LG190178
  • HY-158115
    NST-628

    		Molecular Glues Raf MEK Cancer
    NST-628 is a brain-permeable MAPK pathway molecule glue that inhibits RAF phosphorylation and MEK activation. NST-628 also binds RAF and prevents the formation of BRAF-CRAF and BRAF-ARAF heterodimers, effectively inhibiting the RAS-MAPK pathway. NST-628 inhibits RAS- and RAF-driven cancers and demonstrated potent inhibition in mutant KRAS, NRAS, BRAF class II/III, and NF1-mutant tumors .
    NST-628
  • HY-149537
    TWIK-1/TREK-1-IN-2

    		Potassium Channel Neurological Disease
    TWIK-1/TREK-1-IN-2 (Compound 2g) is a TWIK-1/TREK-1 inhibitor. TWIK-1/TREK-1-IN-2 inhibits TREK-1 homodimer and TWIK-1/TREK-1 heterodimer with IC50s of 10.13 μM and 15.5 μM. TWIK-1/TREK-1-IN-2 is an antidepressant .
    TWIK-1/TREK-1-IN-2
  • HY-110353
    CU-T12-9
    5+ Cited Publications

    		 Toll-like Receptor (TLR) Inflammation/Immunology Cancer
    CU-T12-9 is a specific TLR1/2 agonist with EC50 of 52.9 nM in HEK-Blue hTLR2 SEAP assay. CU-T12-9 activates both the innate and the adaptive immune systems. CU-T12-9 selectively activates the TLR1/2 heterodimer, not TLR2/6. CU-T12-9 signals through NF-κB and invokes an elevation of the downstream effectors TNF-α, IL-10, and iNOS .
    CU-T12-9
  • HY-163801
    Nurr1 agonist 9

    		Nuclear Hormone Receptor 4A/NR4A Neurological Disease
    Nurr1 agonist 9 (Compound 36) is an agonist for Nurr1 with an EC50 of 0.090 µM and a Kd of 0.17 µM. Nurr1 agonist 9 activates the Nurr1 homodimer (NurRE, EC50=0.094 µM) and the Nurr1-RXR heterodimer (DR5, EC50=0.165 µM). Nurr1 agonist 9 induces the expression of Nurr1-regulated tyrosine hydroxylase (TH) in organoid Parkinson's Disease model. Nurr1 agonist 9 is human brain endothelial cell barrier prmeable .
    Nurr1 agonist 9
  • HY-D0932
    Sudan IV

    Solvent Red 24; C.I. 26105

    		 Biochemical Assay Reagents Aryl Hydrocarbon Receptor Cytochrome P450 Metabolic Disease
    Sudan IV is an agonist of the aryl hydrocarbon receptor (AhR) that activates downstream signaling pathways and induces CYP1A1 expression. Sudan IV promotes CYP1A1 gene transcription by activating AhR-ARNT heterodimers and binding to exogenous response elements (XREs) on DNA, thereby enhancing drug metabolizing enzyme activity. Sudan IV can be used to study the toxicity mechanisms of industrial dyes and the effects of interactions with serum proteins (such as bovine serum albumin (BSA)) on their distribution in vivo. Sudan IV is a fat-soluble diazo dye that can be used to stain lipids, triglycerides, and lipoproteins on frozen sections .
    Sudan IV
  • HY-122566
    SMU127

    ZINC666243

    		 Toll-like Receptor (TLR) TNF Receptor Cancer
    SMU127 is an agonist of the toll-like receptor 1/2 (TLR1/2) heterodimer. It induces NF-κB signaling in cells expressing human TLR2 (EC50=0.55 μM) but not cells expressing human TLR3, -4, -5, -7, or -8 when used at concentrations ranging from 0.1 to 100 μM. SMU127 induces the production of TNF-α in isolated human peripheral blood mononuclear cells (PBMCs) when used at concentrations ranging from 0.01 to 1 μM. In vivo, SMU127 (0.1 mg/animal) reduces tumor volume in a 4T1 murine mammary carcinoma model.
    SMU127
  • HY-15128R
    9-cis-Retinoic acid (Standard)

    Alitretinoin (Standard)

    		 Reference Standards RAR/RXR Apoptosis Endogenous Metabolite Neurological Disease Inflammation/Immunology Cancer
    9-cis-Retinoic acid (Standard) is the analytical standard of 9-cis-Retinoic acid. This product is intended for research and analytical applications. 9-cis-Retinoic acid (ALRT1057), a vitamin A derivative, is a potent RAR/RXR agonist. 9-cis-Retinoic acid induces apoptosis, regulates cell cycle and has anticancer, anti-inflammatory and neuroprotection activities[1][2][3][4][5].
    9-cis-Retinoic acid (Standard)
  • HY-15128
    9-cis-Retinoic acid
    2 Publications Verification

    Alitretinoin

    		 RAR/RXR Apoptosis Endogenous Metabolite Neurological Disease Inflammation/Immunology Cancer
    9-cis-Retinoic acid (ALRT1057), a vitamin A derivative, is a potent RAR/RXR agonist. 9-cis-Retinoic acid induces apoptosis, regulates cell cycle and has anticancer, anti-inflammatory and neuroprotection activities .
    9-cis-Retinoic acid

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: